Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Psych MEQs / SAQsProfessional practice — epidemiology and public mental health

Psych MEQs / SAQs · Professional practice — epidemiology and public mental health

Epidemiology and public mental health — service planning MEQ

FRANZCP/MRCPsych-style MEQ integrating epidemiological measures, GBD burden, Rose/Gordon prevention, and treatment-gap service design.

20 marks20 min1 min readVerification in progress

Target exams

FRANZCPMRCPsychABPNMD-DNB
On this page
Study tools

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
You are the psychiatry registrar advising a district planning committee. Local politicians claim 'mental illness is rare' because hospital admission rates are low. A recent household survey (CIDI-based, 12-month prevalence) shows common mental disorders are common, with large unmet need among both mild and severe cases. Youth advocates demand school programmes; the finance officer wants only high-risk clinic expansion. (i) Define incidence, point prevalence, period prevalence, and lifetime prevalence, and state which best informs current service need. (ii) Explain why hospital admission rates are a poor estimate of community burden. (iii) Using GBD language, outline how mental disorders contribute to population health loss (YLD/YLL/DALY). (iv) Apply Rose and Gordon frameworks to recommend a mixed prevention package for the district. (v) Define the treatment gap and list three system strategies to reduce it. (20 marks)

Model answer

Reveal model answerShowHide

(i) Measures. Incidence: new cases per population-time. Point prevalence: cases at one time point. Period prevalence: cases during an interval (e.g. 12 months). Lifetime prevalence: ever meeting criteria up to assessment (recall-sensitive). Current service need is best informed by period (especially 12-month) prevalence plus severity/disability and treatment coverage, not lifetime prevalence alone.[3]

(ii) Admissions ≠ burden. Hospital rates reflect bed supply, thresholds for admission, community alternatives, legal pathways, and help-seeking — not community incidence. Selection enriches severity and comorbidity. Without a population denominator and survey sampling frame, rarity of admissions cannot prove rarity of disorder.[8][3]

(iii) GBD language. Mental disorders generate large YLDs (non-fatal disability). YLLs from mental disorders as underlying cause are relatively lower than for many physical NCDs, but suicide and excess medical mortality are critical mortality pathways. DALYs = YLDs + YLLs support priority setting across diseases.[1][2]

(iv) Prevention mix. Gordon: universal (school mental health curricula, social protection policies), selective (perinatal high-risk, unemployment/ACE-exposed families), indicated (subthreshold depression/anxiety; clinical high-risk psychosis pathways where appropriate).[5] Rose: do not rely only on high-risk clinics — population strategies that shift mean risk (poverty reduction, alcohol policy, anti-bullying) prevent cases arising from the average-risk majority (prevention paradox).[4] Finance officer's clinic-only plan is necessary but insufficient.

(v) Treatment gap and strategies. Treatment gap = proportion of people with mental disorders not receiving treatment.[6] Strategies: (1) stepped care / primary care collaborative care for common disorders; (2) task-sharing and protocolised packages where specialist scarcity exists; (3) anti-stigma and access redesign plus rebalancing from inefficient hospital-only spend toward community coverage (scarcity–inequity–inefficiency triad).[7][3]

Psychiatry Fellowship Pro

Continue reading

You have read the opening of this meqs / saq. The complete unit — every section and its primary-source references — is part of the Psychiatry Fellowship fellowship library.

Sign in to continueSee pricing
References8ShowHide
  1. [1]Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010 Lancet, 2013.PMID 23993280
  2. [2]GBD 2019 Mental Disorders Collaborators Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019 Lancet Psychiatry, 2022.PMID 35026139
  3. [3]Demyttenaere K, Bruffaerts R, Posada-Villa J, et al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys JAMA, 2004.PMID 15173149
  4. [4]Rose G Sick individuals and sick populations Int J Epidemiol, 2001.PMID 11416056
  5. [5]Gordon RS Jr An operational classification of disease prevention Public Health Rep, 1983.PMID 6856733
  6. [6]Kohn R, Saxena S, Levav I, Saraceno B The treatment gap in mental health care Bull World Health Organ, 2004.PMID 15640922
  7. [7]Saxena S, Thornicroft G, Knapp M, Whiteford H Resources for mental health: scarcity, inequity, and inefficiency Lancet, 2007.PMID 17804062
  8. [8]von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies Lancet, 2007.PMID 18064739
Psychiatry Fellowship Pro

$29/ monthor $279 / year

The complete Psychiatry Fellowship library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousEpidemiologic measures and inference in psychiatry (MEQ)Foundations — epidemiologic methods for psychiatryNextEPS spectrum and tardive dyskinesia management (MEQ)Psychopharmacology